

Jordon Jaggers, MD¹ Upeka Samarakoon, PhD, MPH² Xiaoqing Fu, MS² Daniela Kroshinsky, MD, MPH^{3,4} Fatima Bassir, MPH⁵ Abigail Salem, BA⁵ Elizabeth Phillips, MD^{6,7} Liqin Wang, PhD^{4,5} Li Zhou, MD, PhD^{4,5} Kimberly G. Blumenthal, MD, MSc^{2,4*} ¹Department of Medicine, Massachusetts General Hospital, Boston, MA, USA ³Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA ⁴Harvard Medicine, Brigham and Women's Hospital, Boston, MA, USA ⁶Department of Medicine, Center for Drug Safety and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA ⁷Institute for Immunology and Infectious Diseases, Murdoch, Western Australia, Australia *These authors contributed equally

DRESS syndrome survivors have medical and skin sequelae with a substantial impact on quality of life.

INTRODUCTION

- While many may fully recover from drug reaction with eosinophilia ar symptoms (DRESS) syndrome, some have persistent morbidity.
- Health-related quality of life (QOL) after DRESS is not well character

OBJECTIVE

 We aimed to characterize sequelae and QOL associated with DRESS survivorship.

METHODS

- DRESS cases from Mass General Brigham were identified utilizing in methods and manually confirmed with chart review and RegiSCAR so
- We characterized sequelae and QOL using an electronic questionnai
- The Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) was translated and adapted from Baiardini I, et al . Ann Allergy Asthma Im content and face validity.
- DrHy-Q includes 15 statements, following which participants identify following: "Extremely," "Very," "Moderately," "Slightly," or "Not At All."
- Forty DRESS participants responded to the questionnaire (**Table 1**).
- Participants had acute DRESS syndrome a mean 5.6 years (SD 3.4 years) prior to completing the electronic questionnaire.

RESULTS

Table 1. DRESS Pa	rticipar
Demographics	n (otherv
Age (years), Mean \pm SD	54
Female	
Race	
White	
Black	
Asian	

Drug Reaction with Eosinophilia and Systemic Symptoms Sequelae

nd systemic	 Many DRESS survivors reported some of 	dearee of fea				
	their problem with medications, and repo	•				
rized.	•	Many organ problems were reported (Table 3). Skin				
S	DrHy-Q Sta					
	I am afraid that in an emergency I might be give	I am afraid that in an emergency I might be given a drug I am				
	For every illness, I would like to be certain that there is a drug					
	I would like the opinion of an allergist before I take drugs pres					
nformatics	I feel afraid because of my problem with medic	ations.				
scoring.	The problem of drug reactions affects my life.	The problem of drug reactions affects my life.				
ire.	I worry every time I have to take a drug, even i	I worry every time I have to take a drug, even if it's not the one				
	The idea of taking a drug makes me feel anxious.					
s bidirectionally	I feel anxious because of my problem of drug reactions.					
nmunol. 2011 foi	I find every disease more limiting than other people do becau					
	Even a minor illness becomes a problem for me.					
as one of the	The fact that I can't safely take drugs makes me feel different					
	I'm afraid of not being able to get treatment for pain.					
	I feel distressed because of my problem with adverse drug re-					
	I feel down or depressed because of my proble	I feel down or depressed because of my problem with drug re				
	I've given up recreational opportunities (sports	I've given up recreational opportunities (sports, holidays, trips				
ts (n=40)						
%) (unless vise specified)	Table 3. Specific Seq	uelae				
.4 <u>+</u> 17.4	Regular Visit/Hospitalization for					
25 (63)	Problems Related to	n (*				
20 (00)	Skin	26 (
35 (88)	Infections	10 (
2 (5)	Heart/Blood Vessels	8 (2				
2 (5)	Breathing/Lungs	7 (*				
2(0)	Kidneys					
	Thyroid Digastive/Costraintecting	7 (*				
	Digestive/Gastrointestinal	6 (*				
	Liver	5 (*				

RESULTS

ar of being given a drug to which they are allergic (83%, **Table 2**). Many expressed fear (63%) and anxiety (50%) because of n context of taking a new drug even if not the one that caused DRESS (58%). problems were common, and included: pruritus (40%), rashes (35%), dry skin (33%), hives (23%), flushing (20%).


Table 2. DrHy-Q Results	6						
tatamant	Response n (%)						
statement	"Extremely"	"Very"	"Moderately"	"Slightly"	"Not At All"		
m allergic to.	9 (23)	8 (20)	5 (13)	11 (28)	7 (18)		
ug available that I may safely take.	8 (20)	10 (25)	8 (20)	5 (13)	9 (23)		
escribed by other specialists.	7 (18)	6 (15)	4 (10)	9 (23)	14 (35)		
	6 (15)	6 (15)	4 (10)	9 (23)	15 (38)		
	6 (15)	2 (5)	6 (15)	10 (25)	16 (40)		
one that caused an allergic reaction.	6 (15)	3 (8)	3 (8)	11 (28)	17 (43)		
	6 (15)	2 (5)	3 (8)	11 (28)	18 (45)		
	4 (10)	4 (10)	2 (5)	10 (25)	20 (50)		
ause I cannot take certain drugs.	4 (10)	2 (5)	5 (13)	9 (23)	20 (50)		
	3 (8)	3 (8)	3 (8)	9 (23)	22 (55)		
nt from others.	4 (10)	3 (8)	2 (5)	7 (18)	24 (60)		
	3 (8)	4 (10)	3 (8)	5 (13)	25 (63)		
reactions.	3 (8)	2 (5)	4 (10)	6 (15)	25 (63)		
reactions.	3 (8)	2 (5)	4 (10)	2 (5)	29 (73)		
os) because of my problem with drug reactions.	1 (3)	3 (8)	3 (8)	1 (3)	31 (80)		

LIMITATIONS

- %) (65) (25) 20) 18) 18) 18) 15) 5 (13)
- Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) has not yet been validated in English.
- Participants may not be representative due to nonresponder bias.

CONCLUSIONS

- DRESS survivors report longitudinal health problems across diverse organ systems.
- Skin problems were most common, including drug rashes in over one-third.
- DrHy-Q responses indicate DRESS has substantial QOL impact.
- Detailed sequelae studies can inform DRESS follow-up care recommendations.



Funded by NIH/NIAID R01 AI150295